Publications in collaboration with researchers from Rabin Medical Center (13)

2018

  1. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

    Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227

2014

  1. Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels

    BMC Infectious Diseases, Vol. 14, Núm. 1

2013

  1. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255

2011

  1. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

    European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384

  2. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study

    European Journal of Haematology, Vol. 86, Núm. 1, pp. 23-31

2010

  1. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

    Blood, Vol. 116, Núm. 19, pp. 3743-3750

2009

  1. A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

    CLINICAL LYMPHOMA & MYELOMA

  2. Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

    CLINICAL LYMPHOMA & MYELOMA

  3. Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

    CLINICAL LYMPHOMA & MYELOMA

  4. Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

    CLINICAL LYMPHOMA & MYELOMA

  5. VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

    CLINICAL LYMPHOMA & MYELOMA

  6. VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

    CLINICAL LYMPHOMA & MYELOMA

2008

  1. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

    New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917